Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Anticoagulants and breast cancer survival, a nationwide cohort study.

Kinnunen PT, Murto MO, Artama M, Pukkala E, Visvanathan K, Murtola TJ.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 25. pii: cebp.0147.2019. doi: 10.1158/1055-9965.EPI-19-0147. [Epub ahead of print]

PMID:
31653681
2.

Reply to: "calcium channel blockers therapy and the risk of prostate cancer death".

Santala EEE, Rannikko A, Murtola TJ.

Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32745. [Epub ahead of print] No abstract available.

PMID:
31633796
3.

Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.

Siltari A, Riikonen J, Fode M, Murtola TJ.

J Sex Med. 2019 Oct;16(10):1597-1605. doi: 10.1016/j.jsxm.2019.07.001. Epub 2019 Aug 9.

PMID:
31405764
4.

Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland.

Santala EEE, Kotsar A, Veitonmäki T, Tammela TLJ, Murtola TJ.

Scand J Urol. 2019 Jun 28:1-8. doi: 10.1080/21681805.2019.1634147. [Epub ahead of print]

PMID:
31250699
5.

Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.

Joentausta RM, Murtola TJ.

Prostate. 2019 Sep;79(12):1420-1421. doi: 10.1002/pros.23870. Epub 2019 Jun 24. No abstract available.

PMID:
31233216
6.

Access and concentrations of atorvastatin in the prostate in men with prostate cancer.

Knuuttila E, Riikonen J, Syvälä H, Auriola S, Murtola TJ.

Prostate. 2019 Sep;79(12):1412-1419. doi: 10.1002/pros.23863. Epub 2019 Jun 24.

PMID:
31231865
7.

Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.

Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Cancer Causes Control. 2019 Aug;30(8):877-888. doi: 10.1007/s10552-019-01195-x. Epub 2019 Jun 17.

PMID:
31209595
8.

Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study.

Salminen AP, Koskinen I, Perez IM, Hurme S, Murtola TJ, Vaarala MH, Nykopp TK, Seppänen M, Isotalo T, Marttila T, Levomäki L, Becker S, Anttinen M, Liukkonen T, Säily M, Pogodin-Hannolainen D, Viitanen J, Palmberg C, Ottelin J, Sairanen J, Ettala OO, Boström PJ.

Eur Urol Oncol. 2018 Dec;1(6):525-530. doi: 10.1016/j.euo.2018.06.014. Epub 2018 Jul 14.

PMID:
31158099
9.

Aspirin and Prostate Cancer Mortality: The Role of Tumor Grading Misclassification?

Murtola TJ, Veitonmäki T.

Ann Intern Med. 2019 Apr 2;170(7):499-500. doi: 10.7326/M19-0525. Epub 2019 Mar 5. No abstract available.

PMID:
30831583
11.

Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort.

Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Scand J Urol. 2018 Oct - Dec;52(5-6):321-327. doi: 10.1080/21681805.2018.1559882. Epub 2019 Jan 30.

PMID:
30698056
12.

Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):483-490. doi: 10.1038/s41391-019-0129-2. Epub 2019 Jan 29.

PMID:
30696944
13.

Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Sälli SM, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):453-460. doi: 10.1038/s41391-018-0123-0. Epub 2019 Jan 24.

PMID:
30679762
14.

Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.

Joentausta RM, Rannikko A, Murtola TJ.

Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16.

PMID:
30652328
15.

Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.

Østergren PB, Murtola TJ, Fode M.

Eur Urol. 2019 Jun;75(6):938-939. doi: 10.1016/j.eururo.2018.12.016. Epub 2018 Dec 17. No abstract available.

PMID:
30573315
16.

Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.

Rantaniemi L, Tammela TLJ, Kujala P, Murtola TJ.

Scand J Urol. 2018 Aug;52(4):269-276. doi: 10.1080/21681805.2018.1492967. Epub 2018 Oct 26.

PMID:
30362865
17.

Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.

Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):66-76. doi: 10.1038/s41391-018-0087-0. Epub 2018 Sep 13.

PMID:
30214034
18.

Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study.

Santala EE, Rannikko A, Murtola TJ.

Int J Cancer. 2019 Feb 1;144(3):440-447. doi: 10.1002/ijc.31802. Epub 2018 Nov 5.

PMID:
30110124
19.

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

Murtola TJ, Syvälä H, Tolonen T, Helminen M, Riikonen J, Koskimäki J, Pakarainen T, Kaipia A, Isotalo T, Kujala P, Tammela TLJ.

Eur Urol. 2018 Dec;74(6):697-701. doi: 10.1016/j.eururo.2018.06.037. Epub 2018 Jul 18.

PMID:
30031572
20.

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.

Kaapu KJ, Rantaniemi L, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Sci Rep. 2018 Jul 9;8(1):10308. doi: 10.1038/s41598-018-28541-4.

21.

Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.

Mäkelä VJ, Kotsar A, Tammela TLJ, Murtola TJ.

J Urol. 2018 Oct;200(4):743-748. doi: 10.1016/j.juro.2018.04.082. Epub 2018 May 3.

PMID:
29730200
22.

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A.

Br J Cancer. 2018 May;118(9):1248-1254. doi: 10.1038/s41416-018-0055-4. Epub 2018 Mar 22.

23.

Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study.

Murto MO, Artama M, Pukkala E, Visvanathan K, Murtola TJ.

Int J Cancer. 2018 Jun 1;142(11):2227-2233. doi: 10.1002/ijc.31250. Epub 2018 Jan 23.

24.

Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):373-378. doi: 10.1038/s41391-017-0031-8. Epub 2017 Dec 22.

PMID:
29273728
25.

A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H.

Eur Urol Focus. 2019 Jul;5(4):561-567. doi: 10.1016/j.euf.2017.11.002. Epub 2017 Nov 11.

PMID:
29137895
26.

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.

Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

BMC Cancer. 2017 Aug 29;17(1):585. doi: 10.1186/s12885-017-3579-8.

27.

Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.

Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman UH, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2018 Dec;4(6):851-857. doi: 10.1016/j.euf.2017.03.005. Epub 2017 Mar 24.

PMID:
28753870
28.

Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2017 Apr;3(2-3):212-220. doi: 10.1016/j.euf.2016.05.004. Epub 2016 Jun 2.

PMID:
28753762
29.

Components of metabolic syndrome and prognosis of renal cell cancer.

Eskelinen TJ, Kotsar A, Tammela TLJ, Murtola TJ.

Scand J Urol. 2017 Dec;51(6):435-441. doi: 10.1080/21681805.2017.1352616. Epub 2017 Jul 26.

PMID:
28743221
30.

The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.

Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate. 2017 Jun;77(9):1029-1035. doi: 10.1002/pros.23359.

PMID:
28480542
31.

Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.

Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A.

J Urol. 2017 Aug;198(2):305-309. doi: 10.1016/j.juro.2017.02.069. Epub 2017 Feb 16.

PMID:
28216328
32.

Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.

Wettstein MS, Saba K, Umbehr MH, Murtola TJ, Fankhauser CD, Adank JP, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C.

Prostate. 2017 Apr;77(5):549-556. doi: 10.1002/pros.23296. Epub 2017 Jan 17.

33.

Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A.

Scand J Urol. 2017 Feb;51(1):5-12. doi: 10.1080/21681805.2016.1271353. Epub 2017 Jan 13.

PMID:
28084175
34.

Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.

Syvälä H, Pennanen P, Bläuer M, Tammela TL, Murtola TJ.

Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):46-50. doi: 10.1016/j.bbrc.2016.11.021. Epub 2016 Nov 8.

PMID:
27833018
35.

Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Kinnunen PT, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A.

Scand J Urol. 2016 Dec;50(6):413-419. Epub 2016 Sep 14.

PMID:
27628763
36.

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Kaapu KJ, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A.

Br J Cancer. 2016 Nov 22;115(11):1289-1295. doi: 10.1038/bjc.2016.328. Epub 2016 Oct 18.

37.

Tumor features and survival after radical prostatectomy among antidiabetic drug users.

Joentausta RM, Kujala PM, Visakorpi T, Tammela TL, Murtola TJ.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):367-373. doi: 10.1038/pcan.2016.32. Epub 2016 Aug 9.

PMID:
27502739
38.

The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.

Pennanen P, Syvälä H, Bläuer M, Savinainen K, Ylikomi T, Tammela TLJ, Murtola TJ.

Eur J Pharmacol. 2016 Oct 5;788:160-167. doi: 10.1016/j.ejphar.2016.06.036. Epub 2016 Jun 21.

PMID:
27341997
39.

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial.

Veitonmäki T, Murtola TJ, Talala K, Taari K, Tammela T, Auvinen A.

PLoS One. 2016 Apr 21;11(4):e0153413. doi: 10.1371/journal.pone.0153413. eCollection 2016.

40.

Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.

Salminen JK, Tammela TL, Auvinen A, Murtola TJ.

Cancer Causes Control. 2016 May;27(5):637-45. doi: 10.1007/s10552-016-0737-2. Epub 2016 Apr 1.

PMID:
27038166
41.

Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.

Sarre S, Määttänen L, Tammela TL, Auvinen A, Murtola TJ.

Scand J Urol. 2016 Aug;50(4):267-73. doi: 10.3109/21681805.2016.1145734. Epub 2016 Feb 29.

PMID:
26927237
42.

5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A.

Int J Cancer. 2016 Jun 15;138(12):2820-8. doi: 10.1002/ijc.30017. Epub 2016 Feb 11.

43.

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. Epub 2015 Dec 29.

44.

Statin use and risk of disease recurrence and death after radical prostatectomy.

Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ.

Prostate. 2016 Apr;76(5):469-78. doi: 10.1002/pros.23138. Epub 2015 Dec 22.

PMID:
26689439
45.

Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.

Kaapu KJ, Murtola TJ, Määttänen L, Talala K, Taari K, Tammela TL, Auvinen A.

Cancer Causes Control. 2016 Feb;27(2):157-64. doi: 10.1007/s10552-015-0693-2. Epub 2015 Nov 16.

PMID:
26573846
46.

Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A.

Prostate. 2015 Sep;75(13):1394-402. doi: 10.1002/pros.23020. Epub 2015 Jun 12.

PMID:
26073992
47.

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):264-9. doi: 10.1038/pcan.2015.19. Epub 2015 May 5.

48.

Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.

Murtola TJ, Wahlfors T, Haring A, Taari K, Stenman UH, Tammela TL; PRACTICAL Consortium, Schleutker J, Auvinen A.

Eur Urol. 2015 Dec;68(6):1089-97. doi: 10.1016/j.eururo.2015.03.026. Epub 2015 Mar 26.

PMID:
25819720
49.

Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study.

Kaapu KJ, Ahti J, Tammela TL, Auvinen A, Murtola TJ.

Int J Cancer. 2015 Sep 1;137(5):1187-95. doi: 10.1002/ijc.29470. Epub 2015 Feb 20.

50.

Statins and biochemical recurrence after radical prostatectomy - who benefits?

Murtola TJ.

BJU Int. 2014 Nov;114(5):634-5. doi: 10.1111/bju.12794. No abstract available.

Supplemental Content

Loading ...
Support Center